NEW YORK (GenomeWeb News) — Ambit Biosciences today said it will combine its KinomeScan-driven discovery technology with Cephalon's chemistry and discovery and development chops to help develop kinase inhibitors.
Terms of the deal call for Ambit to screen a “large” library of Cephalon’s kinase-focused compounds to generate “nearly a million data points,” Ambit said. In return, Cephalon will pay Ambit $18 million in an up-front fee to access its KinomeScan technology.
The companies will also partner in two programs targeting undisclosed kinases. Terms of those deals give Ambit the responsibility for delivering clinical candidates that Cephalon will further develop in exchange for $232.5 million in additional milestones to Ambit, as well as royalties.
Ambit will also use Cephalon library compounds to discover and develop products that are effective inhibitors of certain undisclosed kinases, the company said.